Related Experiment Video

Updated: Sep 8, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.6K

Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment

Api Talom1, Ankurika Barhoi1, Taba Jirpu1

  • 1Molecular Biology and Biomarker Discovery Laboratory, Department of Zoology, Rajiv Gandhi University, Itanagar, Arunachal Pradesh, India.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|July 13, 2025
PubMed

Insights

Histone deacetylase inhibitors (HDACIs) show promise in cancer treatment by targeting epigenetic dysregulation. Understanding their pharmacokinetics and pharmacodynamics is crucial for improving efficacy, especially in solid tumors through combination therapies.

Area of Science:

  • Cancer Biology
  • Epigenetics
  • Pharmacology

Background:

  • Epigenetic dysregulation, particularly histone acetylation, is a hallmark of cancer.
  • Histone deacetylases (HDACs) remove acetyl groups, leading to chromatin condensation and promoting oncogenesis.
  • Histone deacetylase inhibitors (HDACIs) are investigated as anticancer therapeutics.

Purpose of the Study:

  • To review the role of HDACs in tumor formation.
  • To analyze HDACIs in clinical trials for various malignancies.
  • To explore combination therapies involving HDACIs to overcome monotherapy limitations in solid tumors.

Main Methods:

  • Literature review of HDAC functions in tumorigenesis.
  • Analysis of clinical trial data for HDACIs.
  • Evaluation of synergistic effects in combination cancer therapies.

Main Results:

  • HDACs play a significant role in cancer development.
  • HDACIs are approved for hematological malignancies but show limited efficacy as monotherapy in solid tumors.
  • Combination therapies with HDACIs and FDA-approved drugs demonstrate potential to enhance treatment outcomes.

Conclusions:

  • Thorough understanding of HDACI pharmacokinetics and pharmacodynamics is essential.
  • Combination strategies are promising for improving the therapeutic potential of HDACIs in solid tumors.
  • This review offers insights into novel perspectives for cancer treatment using HDACIs.
Keywords:
CancerCombination therapyEpigenetic regulationHistone deacetylasesInhibitorsSolid tumours

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.6K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K